In a significant milestone for consumer genetics, 23andMe, headquartered in Sunnyvale, CA, has successfully raised $74,700,000 in its latest funding round. Founded in 2006 with a mission to help people access, understand, and benefit from the human genome, 23andMe has long revolutionized the way individuals engage with their genetic information. The company’s trailblazing initiatives have made it the only organization to receive multiple FDA authorizations for genetic health risk reports while also building the world’s largest crowdsourced platform for genetic research, where 80 percent of its customers actively participate. This new injection of capital will fuel further advancements in expanding its robust research platform, accelerating drug discovery programs, and deepening its investigations into the genetic underpinnings of complex diseases and conditions such as oncology, respiratory, and cardiovascular diseases.
With over 180 research publications already to its name, the funding will not only bolster its already impressive portfolio of scientific contributions but also empower the 23andMe Therapeutics group to explore innovative therapeutic avenues rooted in human genetics. As the company continues to pioneer direct access to personalized genetic information, this financial boost is set to enhance the breadth of its genetic insights and deepen its commitment to transforming healthcare. Recognized for its remarkable workplace culture—with accolades such as San Francisco Chronicle's Top Workplaces and Comparably’s Best Places to Work—the company aims to steward this capital to drive both scientific breakthroughs and positive societal health impacts. For more details about the company and its ongoing initiatives, please visit www.23andMe.com.
